Women's experiences of publicly funded non-invasive prenatal testing in Ontario, Canada: Considerations for health technology policy-making

Qualitative Health Research

Volumn 25, Issue 8, 2015, Pages 1069-1084

  Vanstone, Meredith ^a   Yacoub, Karima ^a   GIacomini, Mita ^a   Hulan, Danielle ^a   McDonald, Sarah ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

health policy; health technology; non invasive prenatal testing; Ontario Canada; patient values; prenatal screening; prenatal testing; qualitative research

Indexed keywords

ADULT; BLOOD EXAMINATION; DECISION MAKING; FEMALE; FINANCIAL MANAGEMENT; GENETIC SCREENING; GROUNDED THEORY; HUMAN; ONTARIO; POLICY; PREGNANCY; PRENATAL CARE; PSYCHOLOGY; QUALITATIVE RESEARCH; SOCIOECONOMICS; TIME FACTOR;

ADULT; DECISION MAKING; FEMALE; FINANCING, GOVERNMENT; GENETIC TESTING; GROUNDED THEORY; HEMATOLOGIC TESTS; HUMANS; ONTARIO; POLICY; PREGNANCY; PRENATAL CARE; QUALITATIVE RESEARCH; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84937432175     PISSN: 10497323     EISSN: 15527557     Source Type: Journal    
DOI: 10.1177/1049732315589745     Document Type: Article

References (74)

1. Allyse M., Sayres L., Goodspeed T., Cho M., (2014). Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. Journal of Perinatology, 34, 429-434.
2. American College of Obstetricians and Gynecologists. (2012). Noninvasive prenatal testing for fetal aneuploidy (Committee Opinion No. 545). Obstetrics & Gynecology, 120, 1532-1534.
3. Anderson G., (1999). Nondirectiveness in prenatal genetics: Patients read between the lines. Nursing Ethics, 6, 126-136.
4. Bekker H., Thornton J. G., Airey C. M., Connelly J. B., Hewison J., Robinson M. B.,. Pearman A. D., (1999). Informed decision making: An annotated bibliography and systematic review. Health Technology Assessment, 3 (1), 1-156.
5. Benn P., Borell A., Chiu R., Cuckle H., Dugoff L., Faas B.,. Norton M., (2013). Position statement from the aneuploidy screening committee on behalf of the board of the international society for prenatal diagnosis, April 2013. Prenatal Diagnosis, 32, 1-2.
6. Benn P., Cuckle H., Pergament E., (2013). Non-invasive prenatal testing for aneuploidy: Current status and future prospects. Ultrasound in Obstetrics & Gynecology, 42, 15-33.
7. Bianchi D. W., Oepkes D., Ghidini A., (2014). Current controversies in prenatal diagnosis 1: Should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women? Prenatal Diagnosis, 34, 6-11.
8. Bianchi D. W., Wilkins-Haug L., (2014). Integration of noninvasive DNA testing for aneuploidy into prenatal care: What has happened since the rubber met the road? Clinical Chemistry, 60, 78-87.
9. Boardman F. K., (2014). The expressivist objection to prenatal testing: The experiences of families living with genetic disease. Social Science & Medicine, 107, 18-25.
10. Canadian Institute for Health Information. (2014). National health expenditure trends 1975-2014. Ottawa, Ontario: Author. Retrieved from http://www.cihi.ca/web/resource/en/nhex-2014-report-en.pdf
11. Carroll J. C., Reid A. J., (1997). Ontario maternal serum screening program: Practices, knowledge and opinions of health care. Canadian Medical Association Journal, 156, 775-784.
12. Centre Hospitalier Universitaire de Quebec. (2013). Study of the efficacy of new non-invasive prenatal tests for screening for fetal trisomies using maternal blood. Retrieved from http://ClinicalTrials.gov/show/NCT01925742
13. Chan Y. M., Leung W. C., Chan W. P., Leung T. Y., Cheng Y. K. Y., Sahota D. S., (2015). Women's uptake of non-invasive DNA testing following a high-risk screening test for trisomy 21 within a publicly funded healthcare system: Findings from a retrospective review. Prenatal Diagnosis, 35, 342-347. doi: 10.1002/pd.4544
14. Charmaz K., (2006). Constructing grounded theory: A practical guide through qualitative analysis. Thousand Oaks, CA: SAGE.
15. Chetty S., Garabedian M. J., Norton M., (2013). Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenatal Diagnosis, 33, 542-546.
16. Chitayat D., Langlois S., Wilson R. D., (2011). Prenatal screening for fetal aneuploidy in singleton pregnancies. Journal of Obstetrics and Gynaecology Canada, 33, 736-750.
17. Chitty L. S., Hill M., White H., Wright D., Morris S., (2012). Noninvasive prenatal testing for aneuploidy-ready for prime time? American Journal of Obstetrics & Gynecology, 206, 269-275.
18. Constantine M., Allyse M., Wall M., De Vries R., Rockwood T., (2013). Imperfect informed consent for prenatal screening: Lessons from the quad screen. Clinical Ethics, 9, 17-27. doi: 10.1177/1477750913511339
19. Corbin J., Strauss A., (2008). Basics of qualitative research: Techniques and procedures for developing grounded theory. Thousand Oaks, CA: SAGE.
20. Deans Z., Newson A. J., (2011). Should non-invasiveness change informed consent procedures for prenatal diagnosis? Health Care Analysis, 19, 122-132.
21. Devers P. L., Cronister A., Ormond K. E., Facio F., Brasington C. K., Flodman P., (2013). Noninvasive prenatal testing/noninvasive prenatal diagnosis: The position of the National Society of Genetic Counselors. Journal of Genetic Counseling, 22, 291-295. doi: 10.1007/s10897-012-9564-0
22. Ferm Widlund K., Gunnarsson C., Nordin K., Hansson M. G., (2009). Pregnant women are satisfied with the information they receive about prenatal diagnosis, but are their decisions well informed? Acta Obstetricia et Gynecologica Scandinavica, 88, 1128-1132. doi: 10.1080/00016340903144246
23. Flick U., (2004). Triangulation in qualitative research. In Flick U., von Kardorff E., Steinke I., (Eds.), A companion to qualitative research (pp. 178-183). Thousand Oaks, CA: SAGE.
24. Flick U., (2008). Managing quality in qualitative research. Thousand Oaks, CA: SAGE.
25. Gamma Dynacare. (2014). OHIP now covers payments for the Harmony Prenatal Test Information Bulletin. Laval, Québec, Canada: Author.
26. Gekas J., Gondry J., Mazur S., Cesbron P., Thepot F., (1999). Informed consent to serum screening for Down syndrome: Are women given adequate information? Prenatal Diagnosis, 19, 1-7. doi: 10.1002/(sici)1097-0223(199901)19:1<1::aid-pd456>3.0.co;2-s
27. Giacomini M., Hurley J., Gold I., Smith P., Abelson J., (2004). The policy analysis of "values talk": Lessons from Canadian health reform. Health Policy, 67, 15-24.
28. Gigerenzer G., Gaissmaier W., Kurz-Milcke E., Schwartz L. M., Woloshin S., (2007). Helping doctors and patients make sense of health statistics. Psychological Science in the Public Interest, 8, 53-96.
29. Gigerenzer G., Gray J. A. M., (2011). Better doctors, better patients, better decisions: Envisioning health care 2020. Cambridge, MA: MIT Press.
30. Grace G., (1998). Critical policy scholarship: Reflections on the integrity of knowledge and research. In Shacklock G., Smyth J., (Eds.), Being reflexive in critical educational and social research (pp. 202-217). London: Routledge Falmer.
31. Gregg A. R., Gross S. J., Best R., Monaghan K., Bajaj K., Skotko B. G.,. Watson M. S., (2013). ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genetics in Medicine, 15, 395-398.
32. Grimes D. A., Snively G. R., (1999). Patients' understanding of medical risks: Implications for genetic counseling. Obstetrics & Gynecology 93 (6), 910-914.
33. Heyman B., Hundt G., Sandall J., Spencer K., Williams C., Grellier R., Pitson L., (2006). On being at higher risk: A qualitative study of prenatal screening for chromosomal anomalies. Social Science & Medicine, 62, 2360-2372.
34. Hill M., Barrett A. N., White H., Chitty L. S., (2012). Uses of cell free fetal DNA in maternal circulation. Best Practice & Research Clinical Obstetrics & Gynaecology, 26, 639-654.
35. Hill M., Fisher J., Chitty L. S., Morris S., (2012). Women's and health professionals' preferences for prenatal tests for Down syndrome: A discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests. Genetics in Medicine, 14, 905-913.
36. Hill M., Karunaratna M., Lewis C., Forya F., Chitty L., (2013). Views and preferences for the implementation of non-invasive prenatal diagnosis for single gene disorders from health professionals in the United Kingdom. American Journal of Medical Genetics. Part A, 161, 1612-1618.
37. Hofmann B. M., (2008). Why ethics should be part of health technology assessment. International Journal of Technology Assessment in Health Care, 24, 423-429.
38. Hunt L. M., deVoogd K. B., (2003). Autonomy, danger, and choice: The moral imperative of an "at risk" pregnancy for a group of low-income Latinas in Texas. In Harthorn B., Oaks L., (Eds.), Risk, culture, and health inequality: Shifting perceptions of danger and blame (pp. 74-103). Westport, CT: Greenwood.
39. Jaques A. M., Sheffield L. J., Halliday J. L., (2005). Informed choice in women attending private clinics to undergo first trimester screening for Down syndrome. Prenatal Diagnosis, 25, 656-664. doi: 10.1002/pd.1218
40. Johnson J., Pastuck M., Metcalfe A., Connors G., Krause R., Wilson D., Cuckle H., (2013). First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. Prenatal Diagnosis, 33, 1044-1049. doi: 10.1002/pd.4194
41. Keller C., Siegrist M., (2009). Effect of risk communication formats on risk perception depending on numeracy. Medical Decision Making, 29 (4), 483-490.
42. Kohut R. J., Dewey D., Love E. J., (2002). Women's knowledge of prenatal ultrasound and informed choice. Journal of Genetic Counseling, 11, 265-276.276. doi: 10.1023/a:1016378415514
43. Lafarge C., Mitchell K., Fox P., (2013). Women's experiences of coping with pregnancy termination for fetal abnormality. Qualitative Health Research, 23, 924-936.
44. Langlois S., Brock J., (2013). Current status in non-invasive prenatal detection of Down syndrome, Trisomy 18 and Trisomy 13 using cell-free DNA in maternal plasma. Journal of Obstetrics and Gynaecology Canada, 35, 177-181.
45. Larion S., Warsof S. L., Romary L., Mlynarczyk M., Peleg D., Abuhamad A. Z., (2014). Uptake of noninvasive prenatal testing at a large academic referral center. American Journal of Obstetrics & Gynecology, 211, 651.e1-651.e7.
46. Lewis C., Hill M., Silcock C., Daley R., Chitty L. S., (2014). Non-invasive prenatal testing for trisomy 21: A cross-sectional survey of service users' views and likely uptake. BJOG: An International Journal of Obstetrics and Gynaecology, 121, 582-594. doi: 10.1111/1471-0528.12579
47. Lippman A., (1991). Prenatal genetic testing and screening: Constructing needs and reinforcing inequities. American Journal of Law & Medicine, 17 (1-2), 15-50.
48. Lupton D., (1999). Risk and the ontology of pregnant embodiment. In Lupton D., (Ed.), Risk and sociocultural theory (pp. 59-85). Cambridge, MA: Cambridge University Press.
49. Lupton D., (2011). "The best thing for the baby": Mothers' concepts and experiences related to promoting their infants' health and development. Health, Risk & Society, 13, 637-651.
50. McKechnie A. C., Pridham K., Tluczek A., (2014). Preparing heart and mind for becoming a parent following a diagnosis of fetal anomaly. Qualitative Health Research. Advance online publication. 1049732314553852
51. Ministry of Health and Long-Term Care. (2015). Schedule of benefits for physician services under the Health Insurance Act. Retrieved from http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv-mn.html
52. Miron-Shatz T., Hanoch Y., Graef D., Sagi M., (2009). Presentation format affects comprehension and risk assessment: The case of prenatal screening. Journal of Health Communication, 14, 439-450.
53. Mt. Sinai Hospital. (2015). Reference guide for health care providers: Prenatal Screening Tests for the detection of: Down syndrome, Trisomy 18 and open neural tube defects. Toronto, Ontario: Author. Retrieved from http://www.mountsinai.on.ca/care/family-medicine-genetics-program/prenatal
54. Norton M., Brar H., Weiss J., Karimi A., Laurent L., Caughey A.,. Song K., (2012). Non-Invasive Chromosomal Evaluation (NICE) study: Results of a multi-center prospective cohort study for detection of fetal Trisomy 21 and Trisomy 18. American Journal of Obstetrics & Gynecology, 207, 137.e1-137.e8.
55. Norton M., Rose N. C., Benn P., (2013). Noninvasive prenatal testing for fetal aneuploidy: Clinical assessment and a plea for restraint. Obstetrics & Gynecology, 121, 847-850.
56. Okun N., Summers A., Huang T., Hoffman B., Staines A., Chitayat D., Johnson J. A., (2006). Prospective experience with integrated prenatal screening and first trimester combined screening for Trisomy 21 in a large Canadian urban centre. American Journal of Obstetrics & Gynecology, 195, S193. doi: 10.1016/j.ajog.2006.10.692
57. Öhman S. G., Grunewald C., Waldenström U., (2009). Perception of risk in relation to ultrasound screening for Down's syndrome during pregnancy. Midwifery, 25 (3), 264-276.
58. Prenatal Screening Subcommittee of Ontario. (2015). Prenatal screening Ontario. Toronto: Ontario Ministry of Health and Long-Term Care. Available from http://www.prenatalscreeningontario.ca
59. Public Health Agency of Canada. (2009). What mothers say: The Canadian Maternity Experiences Survey. Ottawa, Ontario: Author.
60. Schwennesen N., Svendsen M. N., Koch L., (2011). Beyond informed choice: Prenatal risk assessment, decision-making and trust. Clinical Ethics, 5, 207-216. doi: 10.1258/ce.2010.010041
61. Silcock C., Liao L.-M., Hill M., Chitty L. S., (2014). Will the introduction of non-invasive prenatal testing for Down's syndrome undermine informed choice? Health Expectations. Advance online publication. doi: 10.1111/hex.12159
62. Statistics Canada. (2012). Women in Canada: A gender-based statistical report (6th ed.). Ottawa, Ontario: Author.
63. Taylor J. B., Chock V. Y., Hudgins L., (2014). NIPT in a clinical setting: An analysis of uptake in the first months of clinical availability. Journal of Genetic Counseling, 23, 72-78.
64. Tischler R., Hudgins L., Blumenfeld Y. J., Greely H. T., Ormond K. E., (2011). Noninvasive prenatal diagnosis: Pregnant women's interest and expected uptake. Prenatal Diagnosis, 31, 1292-1299.
65. Vahanian S. A., Baraa Allaf M., Yeh C., Chavez M. R., Kinzler W. L., Vintzileos A. M., (2013). Patient acceptance of non-invasive testing for fetal aneuploidy via cell-free fetal DNA. The Journal of Maternal-Fetal & Neonatal Medicine, 27, 106-109.
66. van den Heuvel A., Chitty L., Dormandy E., Newson A., Deans Z., Attwood S.,. Marteau T. M., (2010). Will the introduction of non-invasive prenatal diagnostic testing Erode informed choices? An experimental study of health care professionals. Patient Education and Counseling, 78, 24-28.
67. Van den Hof M., Wilson R., (2005). Fetal soft markers in obstetrical ultrasound (SOGC Clinical Practice Guideline). Journal of Obstetrics and Gynecology Canada, 27, 592-612.
68. Vanstone M., King C., de Vrijer B., Nisker J., (2014). Non-invasive prenatal testing: Ethics and policy considerations. Journal of Obstetrics and Gynaecology Canada, 36, 515-526.
69. Vanstone M., Yacoub K., Winsor S., GIacomini M., Nisker J., (2015). What is "NIPT"? Divergent characterizations of non-invasive prenatal testing strategies. American Journal of Bioethics: Empirical Bioethics, 6 (1), 54-67.
70. Wang J.-C., Sahoo T., Schonberg S., Kopita K. A., Ross L., Patek K., Strom C. M., (2015). Discordant noninvasive prenatal testing and cytogenetic results: A study of 109 consecutive cases. Genetics in Medicine, 17, 234-236.
71. Wilson R., (2014). Prenatal screening, diagnosis and pregnancy management of fetal neural tube defects (SOGC Clinical Practice Guideline). Journal of Obstetrics and Gynecology Canada, 36, 927-939.
72. Wilson R. D., Langlois S., Johnson J. A., (2007). Mid-trimester amniocentesis fetal loss rate. Journal of Obstetrics and Gynaecology Canada, 29, 586-595.
73. Wright C., Burton H., (2009). The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update, 15, 139-151.
74. Wright C., Wei Y., Higgins J., Sagoo G., (2012). Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis. BMC Research Notes, 5 (1), Article 476.